Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Receives Average Recommendation of “Buy” from Brokerages

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) has been assigned a consensus rating of “Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, two have assigned a buy recommendation and two have given a strong buy recommendation to the company.

Several analysts have issued reports on the stock. Atb Cap Markets upgraded shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group upgraded Curaleaf to a “strong-buy” rating in a research report on Thursday, October 9th. ATB Capital upgraded shares of Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Alliance Global Partners reiterated a “buy” rating on shares of Curaleaf in a research report on Monday, December 22nd. Finally, Zacks Research raised shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st.

Curaleaf Trading Down 0.9%

OTCMKTS CURLF opened at $2.21 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -6.91 and a beta of 0.74. Curaleaf has a one year low of $0.68 and a one year high of $5.05. The business’s fifty day moving average is $2.69 and its 200-day moving average is $2.60.

Curaleaf (OTCMKTS:CURLF) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. Equities research analysts predict that Curaleaf will post -0.25 EPS for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.